PET and MRI guided adaptive radiotherapy: Rational, feasibility and benefit

被引:9
作者
Thureau, S. [1 ]
Briens, A. [2 ]
Decazes, P. [3 ]
Castelli, J. [2 ,4 ]
Barateau, A. [2 ,4 ]
Garcia, R. [5 ]
Thariat, J. [6 ,7 ,8 ]
de Crevoisier, R. [2 ,4 ]
机构
[1] Univ Rouen, Ctr Henri Becquerel, Dept Radiotherapie & Phys Med, QuantIF EA 4108, F-76000 Rouen, France
[2] Ctr Eugene Marquis, Dept Radiotherapie, Rue Bataille Flandres Dunkerque,CS 44229, F-35042 Rennes, France
[3] Univ Rouen, Ctr Henri Becquerel, Dept Med Nucl, QuantIF EA 4108, Rouen, France
[4] Univ Rennes, INSERM, CLCC Eugene Marquis, LTSI UMR 1099, F-35000 Rennes, France
[5] Inst St Catherine, Serv Phys Med, F-84918 Avignon, France
[6] Ctr Francois Baclesse, Dept Radiat Oncol, F-14000 Caen, France
[7] Normandie Univ, Unicaen, IN2P3 ENSICAEN UMR6534, Lab Phys Corpusculaire, F-14000 Caen, France
[8] ARCHADE Res Community, F-14000 Caen, France
来源
CANCER RADIOTHERAPIE | 2020年 / 24卷 / 6-7期
关键词
PET; MRI; ART; CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; PHASE-I TRIAL; NECK-CANCER; FDG-PET; RADIATION-THERAPY; COMPUTED-TOMOGRAPHY; CERVICAL-CANCER; TUMOR VOLUME; METABOLIC PARAMETERS;
D O I
10.1016/j.canrad.2020.06.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adaptive radiotherapy (ART) corresponds to various replanning strategies aiming to correct for anatomical variations occurring during the course of radiotherapy. The goal of the article was to report the rational, feasibility and benefit of using PET and/or MRI to guide this ART strategy in various tumor localizations. The anatomical modifications defined by scanner taking into account tumour mobility and volume variation are not always sufficient to optimise treatment. The contribution of functional imaging by PET or the precision of soft tissue by MRI makes it possible to consider optimized ART. Today, the most important data for both PET and MRI are for lung, head and neck, cervical and prostate cancers. PET and MRI guided ART appears feasible and safe, however in a very limited clinical experience. Phase I/II studies should be therefore performed, before proposing cost-effectiveness comparisons in randomized trials and before using the approach in routine practice. (C) 2020 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).
引用
收藏
页码:635 / 644
页数:10
相关论文
共 101 条
[81]   Non-18F-FDG PET/CT in the management of patients affected by HNC: state-of-the-art [J].
Quartuccio, Natale ;
Caobelli, Federico ;
Di Mauro, Francesca ;
Cammaroto, Giovanni .
NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (09) :891-898
[82]   Anatomic and dosimetric changes in patients with head and neck cancer treated with an integrated MRI-tri-60Co teletherapy device [J].
Raghavan, Govind ;
Kishan, Amar U. ;
Cao, Minsong ;
Chen, Allen M. .
BRITISH JOURNAL OF RADIOLOGY, 2016, 89 (1067)
[83]   Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer [J].
Rasmussen, Jacob H. ;
Hakansson, Katrin ;
Vogelius, Ivan R. ;
Aznar, Marianne C. ;
Fischer, Barbara M. ;
Friborg, Jeppe ;
Loft, Annika ;
Kristensen, Claus A. ;
Bentzen, Soren M. ;
Specht, Lena .
RADIOTHERAPY AND ONCOLOGY, 2016, 120 (01) :76-80
[84]   Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine:: A substudy of Trans-Tasman Radiation Oncology Group study 98.02 [J].
Rischin, D ;
Hicks, RJ ;
Fisher, R ;
Binns, D ;
Corry, J ;
Porceddu, S ;
Peters, LJ .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2098-2104
[85]   Respiratory-gated (4D) contrast-enhanced FDG PET-CT for radiotherapy planning of lower oesophageal carcinoma: feasibility and impact on planning target volume [J].
Scarsbrook, Andrew ;
Ward, Gillian ;
Murray, Patrick ;
Goody, Rebecca ;
Marshall, Karen ;
McDermott, Garry ;
Prestwich, Robin ;
Radhakrishna, Ganesh .
BMC CANCER, 2017, 17
[86]   Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522 [J].
Schwartz, David L. ;
Harris, Jonathan ;
Yao, Min ;
Rosenthal, David I. ;
Opanowski, Adam ;
Levering, Anthony ;
Ang, K. Kian ;
Trotti, Andy M. ;
Garden, Adam S. ;
Jones, Christopher U. ;
Harari, Paul ;
Foote, Robert ;
Holland, John ;
Zhang, Qiang ;
Quynh-Thu Le .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (04) :721-729
[87]   Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study [J].
Subesinghe, Manil ;
Scarsbrook, Andrew F. ;
Sourbron, Steven ;
Wilson, Daniel J. ;
McDermott, Garry ;
Speight, Richard ;
Roberts, Neil ;
Carey, Brendan ;
Forrester, Roan ;
Gopal, Sandeep Vijaya ;
Sykes, Jonathan R. ;
Prestwich, Robin J. D. .
BMC CANCER, 2015, 15
[88]   Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers [J].
Teng, Feifei ;
Aryal, Madhava ;
Lee, Jae ;
Lee, Choonik ;
Shen, Xioajin ;
Hawkins, Peter G. ;
Mierzwa, Michelle ;
Eisbruch, Avraham ;
Cao, Yue .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (04) :969-977
[89]   MRI-only based radiation therapy of prostate cancer: workflow and early clinical experience [J].
Tenhunen, Mikko ;
Korhonen, Juha ;
Kapanen, Mika ;
Seppala, Tiina ;
Koivula, Lauri ;
Collan, Juhani ;
Saarilahti, Kauko ;
Visapaa, Harri .
ACTA ONCOLOGICA, 2018, 57 (07) :902-907
[90]   Impact of tumour motion compensation and delineation methods on FDG PET-based dose painting plan quality for NSCLC radiation therapy [J].
Thomas, Hannah Mary ;
Kinahan, Paul E. ;
Samuel, James Jebaseelan E. ;
Bowen, Stephen R. .
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2018, 62 (01) :81-90